Signal from the log
Omnio
2,9 M€ · Undisclosed · Sweden · Biotech
Omnio, à Umeå, développe un médicament à base de plasminogène, une protéine naturelle qui aide la peau à nettoyer et refermer une plaie, contre les ulcères du pied diabétique qui ne cicatrisent pas. La levée vient des investisseurs existants, sans fonds nommé ; un premier essai chez des patients est visé en 2027.
Spotted
Announced on , logged by the watch of 1 October 2026.
- Operation
- Funding round
- Announced amount
- 2,9 M€
- Stage
- Undisclosed
- Country
- Sweden
- Sector
- Biotech
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
What is missing before publishing
- No fund is publicly named. It is the first condition of the selection bar: without a named investor there is no round to tell.
Provenance
Source eu-startups
Logged on 1 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.